Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 26, Issue 21, pp. 5579-5587
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 31, 2020
- Revision received July 25, 2020
- Accepted August 24, 2020
- Published first October 14, 2020.
Article Versions
- Previous version (October 14, 2020 - 00:05).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Filip Janku1,*,
- Haeseong Park1,2,
- S. Greg Call1,
- Kiran Madwani1,
- Yasuhiro Oki3,
- Vivek Subbiah1,
- David S. Hong1,
- Aung Naing1,
- Vivianne M. Velez-Bravo1,
- Tamara G. Barnes1,
- Fredrick B. Hagemeister3,
- Gerald S. Falchook1,
- Daniel D. Karp1,
- Jennifer J. Wheler1,
- Sarina A. Piha-Paul1,
- Ignacio Garrido-Laguna1,
- Elizabeth J. Shpall4,
- Luis E. Fayad3,
- Sattva S. Neelapu3,
- Funda Meric-Bernstam1,
- Razelle Kurzrock1, and
- Michelle A. Fanale3
- 1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 2Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri.
- 3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 4Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- ↵*Corresponding Author:
Filip Janku, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0455, Houston, TX 77030. Phone: 713-563-0308; Fax: 713-745-8056; E-mail: fjanku{at}mdanderson.org
November 2020
Volume 26, Issue 21
Volume 26, Issue 21
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Jump to section
Advertisement